

JOURNAL OF LEUKOCYTE BIOLOGY®

An Official Publication of the Society for Leukocyte Biology

Volume 80, Number 5

CONTENTS

November 2006

Introduction

6th International Workshop on HIV, Cells of Macrophage/Dendritic Lineage, and Other Reservoirs

- 961 **Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs.** L. J. Montaner, S. M. Crowe, S. Aquaro, C.-F. Perno, M. Stevenson, and R. G. Collman

Overviews

Defining HIV-1 infection/tropism and HIV envelope-mediated cellular changes

- 965 **HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.** M. M. Goodenow and R. G. Collman
- 973 **HIV accomplices and adversaries in macrophage infection.** S. M. Wahl, T. Greenwell-Wild, and N. Vázquez
- 984 **Type I interferon production in HIV-infected patients.** A. Hosmalin and P. Lebon
- 994 **Role of gp120 in dendritic cell dysfunction in HIV infection.** C. Chougnet and S. Gessani
- 1001 **HIV interactions with dendritic cells: has our focus been too narrow?** H. Donaghy, J. Wilkinson, and A. L. Cunningham

Macrophages as HIV reservoirs

- 1013 **Retroviral E-DNA: persistence and gene expression in nondividing immune cells.** A. Cara and M. E. Klotman
- 1018 **Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence.** E. Cassol, M. Alfano, P. Biswas, and G. Poli

Impact of macrophage activation and function in HIV pathogenesis

- 1031 **Microarray data on gene modulation by HIV-1 in immune cells: 2000–2006.** M. S. Giri, M. Nebozhyn, L. Showe, and L. J. Montaner
- 1044 **Human immunodeficiency virus infection and macrophage cholesterol metabolism.** M. Bukrinsky and D. Sviridov
- 1052 **Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases.** N. L. Webster and S. M. Crowe
- 1067 **The glutamate-glutamine cycle as an inducible, protective face of macrophage activation.** G. Gras, F. Porcheray, B. Samah, and C. Leone

Clinical interventions addressing dendritic cell function, therapy delivery, and macrophage reservoirs

- 1076 **Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV.** S. Trapp, S. G. Turville, and M. Robbiani
- 1084 **Immunostimulatory combinations: designing the next generation of vaccine adjuvants.** R. S. Kornbluth and G. W. Stone
- 1103 **Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.** S. Aquaro, V. Svicher, D. Schols, M. Pollicita, A. Antinori, J. Balzarini, and C. F. Perno

Research Articles

- 1111 **Cytomegalovirus blocks intestinal stroma-induced down-regulation of macrophage HIV-1 infection.** A. Maheshwari, L. E. Smythies, X. Wu, L. Novak, R. Clements, D. Eckhoff, A. J. Lazenby, W. J. Britt, and P. D. Smith

(continued on next page)

- 1118 **Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy.** N. Llewellyn, R. Zioni, H. Zhu, T. Andrus, Y. Xu, L. Corey, and T. Zhu
- 1127 **In vitro modeling of the HIV-macrophage reservoir.** A. Brown, H. Zhang, P. Lopez, C. A. Pardo, and S. Gartner
- 1136 ***Mycobacterium avium*-induced SOCS contributes to resistance to IFN- γ -mediated mycobactericidal activity in human macrophages.** N. Vázquez, T. Greenwell-Wild, S. Rekka, J. M. Orenstein, and S. M. Wahl
- 1145 **Regulation of the tonsil cytokine milieu favors HIV susceptibility.** N. M. Moutsopoulos, N. Vázquez, T. Greenwell-Wild, I. Ecevit, J. Horn, J. Orenstein, and S. M. Wahl
- 1156 **CD16⁺ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells.** P. Ancuta, J. Wang, and D. Gabuzda
- 1165 **Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery.** S. Gorantla, H. Dou, M. Boska, C. J. Destache, J. Nelson, L. Poluektova, B. E. Rabinow, H. E. Gendelman, and R. L. Mosley
- 1175 **Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.** P. E. Kennedy, T. K. Bera, Q.-C. Wang, M. Gallo, W. Wagner, M. G. Lewis, E. A. Berger, and I. Pastan

Editor's Note: Articles in this issue are related to the 6th International Workshop on HIV, Cells of Macrophage/Dendritic Lineage, and Other Reservoirs, held in Varenna, Italy during October 2005. L. J. Montaner served as the editor.

COVER: Representation of HIV-1 phenotypes based on both coreceptor utilization and target tropism *ex vivo*. For more information, see "HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes" (Goodenow and Collman, pages 965–972).